Back

FDA accepts CeleCor’s zalunfiban application, sets June 18, 2027 decision date

Verifying
  • FDA accepted CeleCor Therapeutics’ New Drug Application for investigational zalunfiban.
  • June 18, 2027 is the target action date assigned under PDUFA.
  • CeleBrate’s Phase 3 study found fewer cardiovascular events after rapid STEMI treatment.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.